Research programme: anti-CD160 monoclonal antibodies - Tolerx

Drug Profile

Research programme: anti-CD160 monoclonal antibodies - Tolerx

Alternative Names: Autoimmune disorder therapeutics - Tolerx

Latest Information Update: 26 Feb 2008

Price : $50

At a glance

  • Originator Tolerx
  • Class Monoclonal antibodies
  • Mechanism of Action Cytotoxic T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Autoimmune disorders

Most Recent Events

  • 26 Feb 2008 Discontinued - Preclinical for Autoimmune disorders in USA (Parenteral)
  • 01 Sep 2005 Preclinical trials in Autoimmune disorders in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top